 |
|
|
|
|
|
99mTc-EC-DG
|
|
|
The first radiodiagnostic product based on EC Technology will be
99mTc - labeled deoxyglucose ("99mTc-EC-DG"), a
universal metabolic imaging agent that can diagnose hyper
cellular activity in cancer cells. It will be the first
99mTc labeled sugar analogue developed for use in functional imaging.
The only universal metabolic imaging agent in current use is FDG
which requires a cyclotron to produce the positron emitting
radioisotope fluorine-18 (“ ... full
text
|
|
|
|
|
99mTc-EC-Annexin V
|
|
|
The second imaging agent will be 99m
Tc-EC-annexin V. A clinical pilot study has been completed
and an IND application for a combination Phase I/II clinical
trial study has been submitted to the FDA. The Phase I/II
study, in addition to safety, will assess tumor apoptosis
(programmed cell death) in patients with primary breast cancer
and detect and image treatment related apoptosis in patients
with primary breast cancer. Additional indications will be& ... full
text
|
|
|
|
|
99mTc-EC-LHRH
|
|
|
The third imaging agent will be 99mTc-EC-LHRH. The
company will prepare and file an IND application with the FDA by
the third quarter 2005. The current plan is to commence a
Phase I clinical study in Taiwan to evaluate 99mTc-EC-LHRH
as an agent for the diagnosis of endometriosis and ovarian
cancer. LHRH is a luteinizinghormone releasing hormone
that targets the overexpression of extrogen receptors in
females. Following completion of the Phase ... full
text
|
|
|
|
|
99mTc-EC-MN
|
|
|
The fourth imaging agent will be 99mTc-EC-metronidazole
("99mTc-EC-MN") which will be studied as a cellular
hypoxia targeting agent for oncology and as a functional imaging
agent to assess cardiovascular and neurological disease. The
company is planning to submit an IND application to the FDA in
the third or early fourth quarter 2005 to start a Phase I
clinical trial. The company believes that 99mTc-EC-MN
will be effective in measuring tumor hypo ... full
text
|
|
|
|
|
99mTc-EC-Guanosin
|
|
|
The fifth SPECT
imaging agent is 99mTc-EC-guanosin, a new DNA marker
that is incorporated into DNA/RNA syntheses. 99mTc-EC-guanosin
will initially be studied as a tumor proliferation agent to
differentiate benign and malignant prostate cancer. The agent
will also have application in connection with colorectal cancer,
lung cancer, brain cancer, breast cancer, lymphoma and sarcoma.
The company plans to submit an IN ... full
text
|
|
|
|
|
Radiotherapy Agents
|
|
|
Through EC Technology, new radiotherapeitic agents will be
developed. The company is a strong proponent of the "see and
treat" approach to addressing cancer and other dibilitating
diseases. EC Technology is being used to couple therapeutic
radionuclides, such as Rhenium-188 ("188 Re"), to the
same targeting compounds used for radiodiagnostic purposes. The
objective with each internal radiotherapeutic agent is to
deposit the therapeutic radionuclide directly at t ... full
text
|
|
|
|
|
99mTc-EC-Cox-2
|
|
|
Due to the issues with the FDA
regarding cox-2 inhibitor based products,Cell>Point has delayed its planned
imaging studies with 99mTc-EC-Cox-2 (preferably Celebrex as the Cox-2
inhibitor) to diagnose and characterize colorectal cancer. The recent
pronouncement by the FDA's committee which will likely result in the FDA
allowing Cox-2 inhibitors to be marketed on a somewhat more restricted basis
should allow the imag ... full
text
|
|
|
|
|
68Ga-EC-Guanosin and 68Ga-EC-MN
|
|
|
In addition to diagnostic agents for SPECT imaging, EC
technology will also be used to develop diagnostic agents for
PET imaging. In the Fall of 2003, pre-clinical imaging
studies were conducted with gallium-68 (“68
Ga”) labeled guanosin in rats with lung and breast cancer. The
quality of the images were very encouraging. One of the
objectives of the company is to develop PET agents that use
generator based radioisotopes as opposed to cyclotron based
radioisotopes. ... full
text
|
|
|
|
|
Downstream Products
|
|
|
Other conjugate compounds that the company is working with
include
99mTc-EC labeled neomycin, colchicine, methotrexate, adriamycin,
somatostatin, adenosine, transferrin, androgen, estrogen,
projesterone, carnitine, puromycin, TRAIL, capase-3, angiostatin,
folate, CD40 and gemcitabine. ... full
text
|
|
|
|
|
|
|
r & d
